PLX-3618 selectively degrades BRD4 through the recruitment of DCAF11
July 19, 2024
Plexium Inc. has reported the discovery and preclinical characterization of PLX-3618, a novel monovalent direct degrader of BRD4 being developed for the treatment of cancer.
